" TORONTOâ[Cybin Inc.] [NEO:CYBN] (NYSE American:CYBN) Cybin or the Company, a biopharmaceutical company focused on progressing âPsychedelics to TherapeuticsTMâ, today announced that the first study visit has been conducted in a Cybin-sponsored feasibility study evaluating Kernelâs quantitative neuroimaging technology, Flow, to measure ketamineâs psychedelic effects on cerebral cortex hemodynamics."
You need for vote for yourself aswell
Iâll put a vote down maybe youâll like to look at thread on here for $dea and maybe vote on that stock
1 Like
Thanks Lenny!
1 Like